Display options
Cite
Di Vuolo V, Buonaguro L, Izzo F, et al. TP53 and MDM2 gene polymorphisms and risk of hepatocellular carcinoma among Italian patients. Infect Agent Cancer. 2011;6:13doi: 10.1186/1750-9378-6-13.
Di Vuolo, V., Buonaguro, L., Izzo, F., Losito, S., Botti, G., Buonaguro, F. M., & Tornesello, M. L. (2011). TP53 and MDM2 gene polymorphisms and risk of hepatocellular carcinoma among Italian patients. Infectious agents and cancer, 613. https://doi.org/10.1186/1750-9378-6-13
Di Vuolo, Valeria, et al. "TP53 and MDM2 gene polymorphisms and risk of hepatocellular carcinoma among Italian patients." Infectious agents and cancer vol. 6 (2011): 13. doi: https://doi.org/10.1186/1750-9378-6-13
Di Vuolo V, Buonaguro L, Izzo F, Losito S, Botti G, Buonaguro FM, Tornesello ML. TP53 and MDM2 gene polymorphisms and risk of hepatocellular carcinoma among Italian patients. Infect Agent Cancer. 2011 Aug 15;6:13. doi: 10.1186/1750-9378-6-13. PMID: 21843334; PMCID: PMC3170208.
Copy Download .nbib Format: NLM
Share it on

Infect Agent Cancer. 2011 Aug 15;6:13. doi: 10.1186/1750-9378-6-13.

TP53 and MDM2 gene polymorphisms and risk of hepatocellular carcinoma among Italian patients.

Infectious agents and cancer

Valeria Di Vuolo, Luigi Buonaguro, Francesco Izzo, Simona Losito, Gerardo Botti, Franco M Buonaguro, Maria Lina Tornesello

Affiliations

  1. Molecular Biology and Viral Oncology and AIDS Ref, Centre, National Cancer Institute "Fond, Pascale", Naples, Italy. [email protected].

PMID: 21843334 PMCID: PMC3170208 DOI: 10.1186/1750-9378-6-13

Abstract

BACKGROUND: Single-nucleotide polymorphisms within TP53 gene (codon 72 exon 4, rs1042522, encoding either arginine or proline) and MDM2 promoter (SNP309; rs2279744), have been independently associated with increased risk of several cancer types. Few studies have analysed the role of these polymorphisms in the development of hepatocellular carcinoma.

METHODS: Genotype distribution of TP53 codon 72 and MDM2 SNP309 in 61 viral hepatitis-related hepatocellular carcinoma cases and 122 blood samples (healthy controls) from Italian subjects were determined by PCR and restriction fragment length polymorphism (RFLP).

RESULTS: Frequencies of TP53 codon 72 alleles were not significantly different between cases and controls. A significant increase of MDM2 SNP309 G/G and T/G genotypes were observed among hepatocellular carcinoma cases (Odds Ratio, OR = 3.56, 95% Confidence Limits, 95% CI = 1.3-9.7; and OR = 2.82, 95% CI = 1.3-6.4, respectively).

CONCLUSIONS: These results highlight a significant role of MDM2 SNP309 G allele as a susceptibility gene for the development of viral hepatitis-related hepatocellular carcinoma among Italian subjects.

References

  1. J Cell Mol Med. 2009 Mar;13(3):440-53 - PubMed
  2. Hepatology. 1999 Mar;29(3):697-702 - PubMed
  3. Mol Cell Biol. 1987 Feb;7(2):961-3 - PubMed
  4. Oncogene. 2006 Jun 26;25(27):3756-70 - PubMed
  5. Semin Cancer Biol. 2003 Feb;13(1):49-58 - PubMed
  6. Cancer Res. 1987 Sep 15;47(18):4967-72 - PubMed
  7. Nat Rev Cancer. 2009 Feb;9(2):95-107 - PubMed
  8. Oncogene. 2006 Mar 13;25(11):1602-11 - PubMed
  9. Carcinogenesis. 2008 Jun;29(6):1192-6 - PubMed
  10. Arch Pathol Lab Med. 2002 Oct;126(10):1164-8 - PubMed
  11. Cancer Res. 2005 Jul 1;65(13):5481-4 - PubMed
  12. Cell. 2004 Nov 24;119(5):591-602 - PubMed
  13. World J Gastroenterol. 2009 Nov 28;15(44):5592-7 - PubMed
  14. World J Gastroenterol. 2004 Aug 1;10(15):2223-7 - PubMed
  15. Oncology. 2009;77(5):328-34 - PubMed
  16. Lancet. 1998 Jan 17;351(9097):214-5 - PubMed
  17. Clin Cancer Res. 2006 Aug 15;12(16):4867-71 - PubMed
  18. Cancer Epidemiol. 2010 Aug;34(4):448-52 - PubMed
  19. Int J Cancer. 2011 Jan 1;128(1):176-84 - PubMed
  20. Clin Cancer Res. 2007 Jul 15;13(14):4123-9 - PubMed
  21. Cancer Lett. 2003 Apr 25;193(2):199-205 - PubMed
  22. World J Gastroenterol. 2011 Mar 7;17(9):1211-8 - PubMed
  23. Cancer Lett. 2004 May 10;208(1):75-9 - PubMed
  24. Arch Virol. 2004 Feb;149(2):323-36 - PubMed
  25. Int J Cancer. 2010 Dec 15;127(12):2893-917 - PubMed
  26. Eur J Hum Genet. 2007 Jan;15(1):110-4 - PubMed
  27. Oncogene. 2002 Jul 18;21(31):4801-11 - PubMed
  28. J Hum Genet. 2010 Aug;55(8):518-24 - PubMed
  29. Toxicology. 2002 Dec 27;181-182:39-42 - PubMed
  30. Cancer Detect Prev. 2009;32(5-6):380-5 - PubMed
  31. Lancet. 1997 Oct 18;350(9085):1142-3 - PubMed
  32. Ann Intern Med. 2003 Nov 18;139(10):817-23 - PubMed
  33. Cancer Res. 2006 May 15;66(10):5104-10 - PubMed
  34. Eur J Cancer. 2008 Apr;44(6):847-53 - PubMed
  35. J Biol Chem. 2005 Jul 22;280(29):26776-87 - PubMed
  36. J Cancer Res Clin Oncol. 2011 Jul;137(7):1095-104 - PubMed
  37. Mol Cell Biol. 2003 Jan;23(2):462-72 - PubMed
  38. Am J Hum Genet. 1999 Dec;65(6):1782-5 - PubMed
  39. Cancer Lett. 2009 Dec 1;286(1):9-14 - PubMed
  40. Hepatol Res. 2007 Sep;37(9):748-54 - PubMed
  41. Int J Cancer. 1990 Feb 15;45(2):231-6 - PubMed
  42. Biomarkers. 2011 Feb;16(1):42-50 - PubMed
  43. J Natl Cancer Inst. 2006 Feb 15;98(4):285-8 - PubMed
  44. Br J Cancer. 2006 Feb 13;94(3):446-9 - PubMed
  45. J Med Genet. 2006 Jun;43(6):531-3 - PubMed

Publication Types